



A Case of Lupus Erythematosus–Lichen Planus Overlap Syndrome Presenting as Verrucous Plaque at the Elbow: A Diagnostic Challenge

Authors:	Shrayan Pal, ¹ *Swarnali Maiti ² 1. ICARE Institute of Medical Science & Research, Haldia, India 2. Barasat Government Medical College, India *Correspondence to mswarnali95@gmail.com
Conflicts of interest:	The authors have declared no conflicts of interest.
Funding statement:	The authors declare they received no funding for this study.
Gen AI use:	The authors declare no use of generative AI in this report.
Informed consent:	Written informed consent for publication of their clinical details and clinical images was obtained from the patient.
Peer review:	This article was accepted following double-blind peer review.
Received:	19.01.26
Accepted:	09.09.26
Keywords:	Immunofluorescence, lichen planus (LP), lupus erythematosus (LE), mucin deposition, vacuolar degeneration, verrucous plaque.
Citation:	EMJ Dermatol. 2026; https://doi.org/10.33590/emjdermatol/22195B56

Abstract

Lupus erythematosus–lichen planus (LE–LP) overlap syndrome is a rare clinical disorder, which is characterised by the features of both LE and LP. The authors report a case of a 35-year-old male presenting with an itchy, verrucous annular plaque over the left elbow that had been present for 4 months. There was no history of any pain. Clinical diagnosis was challenging due to the atypical presentation, but histopathology revealed hyperkeratosis, wedge-shaped hypergranulosis, saw-tooth acanthosis, vacuolar degeneration, lymphocytic infiltrates, pigment incontinence, and mucin deposition in the dermis. Immunological evaluation showed positive antinuclear antibody and direct immunofluorescence with granular immunoglobulin and complement component 3 (C3) deposition and linear fibrinogen at the basement membrane zone. The patient was diagnosed with LE–LP overlap syndrome and treated with topical 0.5% clobetasol propionate ointment, and achieved rapid resolution within 3 weeks. This case emphasises the diagnostic complexity of LE–LP overlap syndrome, highlighting the need for histopathological and immunological correlation.

Key Points

1. This case highlights the importance of integrating all the clinical, histopathological, and immunological data to diagnose lupus erythematosus–lichen planus overlap syndrome.
2. This is a case report presenting an unusual presentation on a non-sun-exposed site, emphasising the need for high clinical suspicion and comprehensive evaluation.
3. Clinicians should consider this entity in atypical verrucous plaques or annular lesions, even in non-sun-exposed areas, to avoid diagnostic delays.

INTRODUCTION

Lupus erythematosus (LE) and lichen planus (LP) are chronic immune-mediated inflammatory dermatoses. Although classically regarded as distinct entities, they share several clinical, histopathological, and immunopathogenic features.¹ LE represents a disease spectrum ranging from cutaneous-limited variants like acute, subacute, and chronic cutaneous LE to systemic LE, a potentially life-threatening multisystem disorder.^{1,2} In contrast, LP is a T cell-mediated inflammatory disease, which primarily affects the skin and mucous membranes, and is characterised by pruritic, polygonal, violaceous papules and plaques with a predilection for flexural surfaces and mucosa.³

Despite their different clinical paradigms, both LE and LP are united by the presence of interface dermatitis, a histopathological reaction pattern defined by basal keratinocyte damage, vacuolar alteration, apoptotic bodies, and a lymphocyte-rich infiltrate at the dermo-epidermal junction.⁴ This shared histological substrate underpins the existence of overlap syndromes, in which patients exhibit combined features of both disorders.

LE–LP overlap syndrome was first described by Romero et al.¹ in 1977, who highlighted unusual cases exhibiting mixed clinical morphology and immunopathological findings inconsistent with either disease by itself. Since then, sporadic case reports and small series have appeared in the literature, underscoring the heterogeneity of

presentation and the absence of uniform diagnostic standards until recently.⁵ Historically, such cases were variably labelled as ‘lupus–LP overlap’, ‘lichenoid lupus’, or ‘LP-like lupus’, which reflects an ongoing conceptual ambiguity in literature.

In 2021, Lee et al.² published a review article and proposed diagnostic criteria to standardise the case definition. According to this framework, ‘classic’ LE–LP overlap syndrome requires: (i) mixed clinical features of LE and LP, (ii) LP-predominant histopathology with or without LE features, and (iii) serological evidence of LE, particularly antinuclear antibody (ANA) positivity at titres $\geq 1:160$. ‘Possible’ overlap syndrome is diagnosed when serological criteria are absent, but clinicopathological overlap is convincing.² Importantly, direct immunofluorescence (DIF) demonstrating combined lupus and LP patterns is considered a strong supportive feature.

From an immunopathogenic standpoint, LE–LP overlap syndrome appears to arise from shared immune mechanisms involving cytotoxic (CD8⁺) T cells, plasmacytoid dendritic cells, and Type I interferon (IFN) signalling.^{3,5} IFN- α , a central mediator in LE pathogenesis, has also been implicated in LP and other lichenoid dermatoses, suggesting a continuum of immune activation rather than discrete disease processes.⁵ Genetic susceptibility, environmental triggers, UV radiation, infections, and drugs (including aromatase inhibitors and immune-modulating agents) have all been implicated as potential precipitating factors.^{6,7}

Clinically, most reported cases of LE–LP overlap syndrome involve sun-exposed areas and present as annular, violaceous, or discoid plaques with variable degrees of scale, dyspigmentation, or atrophy.^{8,9} Verrucous or hypertrophic morphology is distinctly uncommon and poses a significant diagnostic challenge, often mimicking hypertrophic LP (HLP), verrucous discoid LE, chronic prurigo, or even squamous cell carcinoma (SCC).^{2,10} Lesions arising on non-sun-exposed sites further obscure clinical suspicion.

The authors report a case of cutaneous-limited LE–LP overlap syndrome presenting as a solitary verrucous plaque on the elbow, an unusual site and morphology, emphasising the importance of clinicopathological correlation, direct immunofluorescence, and serological evaluation in arriving at an accurate diagnosis.

CASE REPORT

A 35-year-old male presented to the dermatology outpatient clinic with a 4-month history of a single, slowly progressive lesion over the left elbow. The lesion was associated with moderate pruritus but was otherwise asymptomatic. It had initially appeared as a small, mildly erythematous papule and gradually increased in size and thickness over several months, developing a rough, hyperkeratotic surface.

There was no history of photosensitivity, oral or genital ulcers, alopecia, Raynaud phenomenon, arthralgia, fever, weight loss, or constitutional symptoms suggestive of systemic LE. The patient denied preceding trauma, insect bite, or local application of topical medications. There was no past history of autoimmune disease, chronic infection, or malignancy. Family history was non-contributory. The patient was not on any long-term medications and denied recent intake of drugs commonly associated with lichenoid eruptions.

On cutaneous examination, a solitary, well-defined verrucous annular plaque of approximately 3.5×2.5 cm was noted on the extensor aspect of the left elbow

(Figure 1A). The lesion showed marked hyperkeratosis with a rough, warty surface, central dyspigmentation, and mild erythema at the periphery. The margins were sharp and the plaque was firm but non-tender on palpation. No Wickham's striae were appreciable. There was no scarring, atrophy, follicular plugging, telangiectasia, or ulceration. On further examination, the scalp, face, trunk, mucosae, nails, and genitalia were unremarkable.

Based on the clinical morphology and distribution of the lesion, provisional differential diagnoses were HLP, prurigo nodularis, hypertrophic discoid LE, cutaneous sarcoidosis, and verrucous SCC.^{8,9}

A punch biopsy was done from the active margin of the lesion. Histopathological examination revealed compact orthokeratotic hyperkeratosis without parakeratosis, irregular acanthosis with saw-tooth elongation of rete ridges, and focal wedge-shaped hypergranulosis, consistent with LP. Also, there was prominent basal cell vacuolar degeneration, apoptotic keratinocytes, thickening of the basement membrane, and a dense, band-like lymphocytic infiltrate at the dermo-epidermal junction (Figure 1B). The inflammatory infiltrates also showed perivascular and peri-adnexal lymphocytic involvement. Marked pigment incontinence with dermal melanophages was present and increased dermal mucin deposition was shown (Figure 1C), which was later confirmed with Alcian blue stain, a feature favouring LE.⁶

DIF was performed on perilesional skin, which showed granular deposition of IgG and complement component 3 (C3) along the dermo-epidermal junction (lupus band) together with linear fibrinogen deposition along the basement membrane zone, a pattern characteristic of LP.⁷

Serological examinations demonstrated a positive ANA test with a speckled pattern at a titre of 1:160. Anti-double-stranded DNA antibodies and extractable nuclear antigen profile were negative. Complete blood count, hepatic enzymes, and renal function tests, urinalysis, and chest radiography were within normal limits.

Figure 1: Figures showing clinical and histopathological images of the presented case.



- A)** Non-tender verrucous annular plaque over the left elbow with some scaling and dyspigmentation.
B) 10x magnification showing hyperkeratosis without any parakeratosis, wedge-shaped hypergranulosis, saw-tooth rete ridges, vacuolar degeneration of the basal cell layer, thickening of the basement membrane, and lymphocytic infiltrates at the dermo-epidermal junction.
C) 40x magnification showing perivascular and peri-adnexal lymphocytic infiltrates, pigment incontinence, and mucin deposition in the dermis.

Based on combined clinical findings, histopathological overlap, dual DIF pattern, and serological positivity, a diagnosis of cutaneous-limited LE–LP overlap syndrome was established. According to the criteria proposed by Lee et al., the case fulfilled criteria for ‘possible’ overlap syndrome.²

The patient was treated with topical clobetasol propionate 0.05% ointment applied twice daily for 3 weeks, along with emollients and photoprotection advice. On follow-up, there was significant reduction in pruritus, marked flattening of the plaque, and reduction in hyperkeratosis, with residual post-inflammatory dyspigmentation. The patient continues to be followed for recurrence or evolution of systemic disease.

DISCUSSION

LE–LP overlap syndrome occupies a unique position within the spectrum of interface dermatoses, representing a convergence of two well-characterised autoimmune diseases. Its rarity, protean manifestations, and histological overlap with pure LE or LP contribute to frequent diagnostic delay or misclassification.^{1,2}

Clinical Spectrum and Diagnostic Pitfalls

The clinical presentation of LE–LP overlap syndrome is highly variable. Lesions may resemble classical LP or discoid LE, or display hybrid morphology with annular configuration, violaceous hue, scaling, dyspigmentation, or atrophy (Table 1).^{2,11} Most reported cases involve sun-exposed areas such as the face, neck, and upper trunk, supporting a role for UV radiation as a triggering factor.²

Verrucous or hypertrophic presentations are very uncommon yet clinically significant. Such lesions may closely mimic HLP, hypertrophic discoid LE, or verrucous SCC. They often prompt us to perform repeated biopsies or unnecessary surgical intervention.^{8,9} The present case is notable for its solitary verrucous plaque on the elbow, a non-sun-exposed site, highlighting

the breadth of clinical expression and the importance of considering overlap syndrome even in atypical settings.

Histopathology and Immunofluorescence

Histopathological evaluation is crucial for accurate diagnosis. LP-predominant features such as hypergranulosis, saw-tooth acanthosis, and band-like lymphocytic infiltrate are typically accompanied by LE-specific findings such as basal vacuolar degeneration, basement membrane thickening, dermal mucin deposition, and peri-adnexal inflammation.⁶ However, similar features may be encountered in hypertrophic LE or lichenoid drug eruptions, limiting diagnostic specificity when histology is interpreted in isolation.

Direct immunofluorescence is therefore invaluable. The demonstration of a lupus band (granular IgG and/or C3 deposition along the dermo-epidermal junction) in combination with linear fibrinogen deposition typical of LP strongly supports an overlap diagnosis.^{2,7} This dual pattern was clearly demonstrated in this case and proved decisive in establishing the diagnosis.

Serology and Systemic Risk

Serological abnormalities in LE–LP overlap syndrome are variable. ANA positivity is reported in a significant proportion of cases, often at low to moderate titres.¹¹ Anti-double-stranded DNA and other lupus-specific autoantibodies are usually absent in cutaneous-limited disease, as observed in this patient. While ANA positivity fulfils diagnostic criteria for classic overlap syndrome, its absence does not exclude the diagnosis.²

The risk of progression to systemic LE appears low but not negligible. Long-term follow-up is therefore recommended, particularly in patients with serological abnormalities or extensive disease.¹²

Table 1: Spectrum of reported clinical presentations of LE–LP overlap syndrome.

Clinical phenotype	Typical clinical features	Reported sites/examples
LP-predominant phenotype	Violaceous, flat-topped, polygonal papules or plaques resembling classical LP	Extremities and trunk
LE/DLE-predominant phenotype	Erythematous or violaceous scaly plaques with central atrophy, dyspigmentation, follicular changes, and/or scarring	Face, trunk, and extremities
Annular/polycyclic phenotype	Annular or polycyclic scaly plaques, sometimes with central atrophy or dyspigmentation	Trunk and extremities; reported particularly with SCLE–LP overlap
Mixed/intermediate phenotype	A single lesion showing simultaneous clinical characteristics of LE and LP	Variable; may occur on trunk or extremities
Polar/coexistent phenotype	Separate lesions with typical LE and LP morphology occurring in the same patient	Multiple anatomical sites
Hypertrophic/hyperkeratotic phenotype	Thick, hyperkeratotic, or verrucous plaques that may clinically mimic hypertrophic LP, verrucous DLE, or SCC	Extremities; elbow and lower limbs reported
Bullous phenotype	Vesicles or bullae developing on lesions with LP/LE features	Face, trunk, and extremities
Mucocutaneous phenotype	Cutaneous lesions accompanied by oral or other mucosal LP-like involvement	Oral mucosa with cutaneous disease
Atypical/SCC-mimicking phenotype	Verrucous, hyperkeratotic, or tumour-like plaques clinically suspicious for SCC	Variable anatomical sites

DLE: discoid lupus erythematosus; LE: lupus erythematosus; LP: lichen planus; SCC: squamous cell carcinoma; SCLE: subacute cutaneous lupus erythematosus.

Pathogenesis

The immunopathogenesis of LE–LP overlap syndrome likely reflects shared immune pathways rather than coincidental coexistence. Both LE and LP are characterised by CD8⁺ T cell-mediated keratinocyte injury and heightened Type I IFN signalling.^{3,5} Plasmacytoid dendritic cells and IFN-α play central roles in sustaining interface inflammation in both diseases.¹³ Drug-induced immune modulation has also been implicated, with reports of overlap syndrome arising in association with the usage of aromatase inhibitors and malignancy-related immune dysregulation.⁵

Management

Management strategies depend upon the disease extent and the severity. Localised

cutaneous disease often responds well to potent topical or intralesional corticosteroids, or topical calcineurin inhibitors.¹⁴ More extensive or hypertrophic lesions may require systemic therapy, including antimalarials such as hydroxychloroquine, or retinoids such as acitretin, or immunosuppressive agents.^{10,15} Recent advances in understanding IFN-driven pathways raise the possibility of targeted biologic therapies in refractory cases.⁵

Differentiation from HLP and Long-Term Outcomes

HLP is an important clinical and histopathological differential diagnosis in verrucous or hypertrophic lesions of LE–LP overlap syndrome. HLP typically presents as intensely pruritic, hyperkeratotic, or

verrucous plaques, often affecting the distal lower extremities, particularly the shins, and may be bilateral or multifocal. In contrast, LE–LP overlap syndrome is uncommon and more frequently demonstrates mixed clinical features of LE and LP, with annular, violaceous, discoid, or atrophic morphology and a tendency to involve photo-exposed sites, although atypical verrucous lesions at non-sun-exposed sites may occur, as in this patient. Histopathologically, both conditions may demonstrate hyperkeratosis, hypergranulosis, saw-toothed acanthosis, basal vacuolar degeneration, and a lichenoid infiltrate. However, wedge-shaped hypergranulosis, hyperorthokeratosis, and irregular psoriasiform epidermal hyperplasia are characteristic supportive features of HLP.^{16,17} In contrast, the presence of prominent basal vacuolar degeneration, basement membrane thickening, peri-adnexal/perivascular inflammation, and dermal mucin favours LE. In the present case, although wedge-shaped hypergranulosis and saw-toothed rete ridges suggested LP/HLP, the associated dermal mucin, prominent peri-adnexal inflammation, positive ANA, and dual DIF pattern provided additional evidence for LE–LP overlap syndrome. The 2025 review by Scotti et al.¹⁶ also emphasises that adequate biopsy depth and clinicopathological correlation are particularly important in distinguishing hypertrophic lichenoid disorders from hypertrophic lupus and SCC.

The two conditions may also differ in their long-term clinical implications. HLP is frequently chronic and therapeutically challenging when extensive, and longstanding hypertrophic lesions warrant surveillance because SCC has been reported to arise within HLP, particularly in lesions of the lower extremities.^{16,18} LE–LP overlap syndrome, in contrast, has a less well-defined natural history because of its rarity and limited long-term follow-up data. The principal concerns are persistence or recurrence of cutaneous disease and, in selected patients, subsequent development of systemic lupus manifestations. Therefore, continued clinical surveillance is appropriate, particularly when lesions are chronic, hypertrophic, ulcerated, rapidly

enlarging, or otherwise clinically suspicious for malignant transformation. However, LP and LE can also coexist in the same patient. Blaschkoid LP in the setting of concurrent childhood-onset systemic LE has been described in literature.¹⁹

Malignant Transformation in Chronic Cutaneous Lupus

Chronic cutaneous LE, particularly longstanding discoid LE (DLE), is associated with an increased risk of cutaneous SCC, although the absolute risk remains relatively low and estimates vary substantially among studies. Traditionally, the risk has been cited at approximately 2–5%, while some older literature and selected series have reported substantially higher figures, approaching 10–15%, particularly in longstanding, hypertrophic, or extensively scarred lesions.^{20–22} More recent systematic and population-based data suggest that SCC arising within DLE remains an uncommon complication, with reported rates generally lower than the highest historical estimates.^{21,22} The risk appears to be influenced by chronic inflammation and scarring, cumulative UV exposure, lesion duration, and anatomical site. SCC arising in DLE may also behave more aggressively than conventional cutaneous SCC, with recurrence and metastatic disease reported in the literature.²¹ Consequently, persistent induration, ulceration, crusting, bleeding, pain, or rapid enlargement of a chronic DLE lesion should prompt biopsy to exclude malignant transformation. Although this patient did not have DLE or evidence of malignancy, recognition of this risk is relevant when considering the long-term implications of lupus-associated hypertrophic or verrucous lesions.

CONCLUSION

LE-LP overlap syndrome is a rare but important diagnostic consideration in patients presenting with chronic, atypical lichenoid or verrucous plaques. This case highlights an unusual presentation on a non-sun-exposed site, emphasising

the need for high clinical suspicion and comprehensive evaluation. Histopathology, direct immunofluorescence, and serological evaluation are the cornerstones for accurate diagnosis. Early recognition enables clinicians to manage appropriately, avoid misdiagnosis, and facilitate long-term monitoring for systemic involvement.

References

- Romero RW et al. Unusual variant of lupus erythematosus or lichen planus. Clinical, histopathologic, and immunofluorescent studies. *Arch Dermatol.* 1977;113(6):741-8.
- Jicha KI et al. Cutaneous lupus erythematosus/lichen planus overlap syndrome. *JAAD Case Rep.* 2021;17:130-51.
- Tziotzios C et al. Lichen planus and lichenoid dermatoses: clinical overview and molecular basis. *J Am Acad Dermatol.* 2018;79(5):789-804.
- Yang HS et al. Lupus erythematosus/lichen planus overlap syndrome in a breast cancer patient receiving aromatase inhibitor: a case report and review of the literature. *Dermatologica Sinica.* 2020;38(2):129-30.
- Wenzel J et al. Type I interferon-associated cytotoxic inflammation in lichen planus. *J Cutan Pathol.* 2006;33(10):672-8.
- Patterson JW, "The lichenoid reaction pattern ('interface dermatitis')," *Weedon's Skin Pathology (2016) 4th edition*, Amsterdam: Elsevier, pp.35-70.e41.
- Camisa C et al. Use of indirect immunofluorescence in the lupus erythematosus/lichen planus overlap syndrome: an additional diagnostic clue. *J Am Acad Dermatol.* 1984;11(6):1050-9.
- Riahi RR, Cohen PR. Hypertrophic lichen planus mimicking verrucous lupus erythematosus. *Cureus.* 2018;10(11):e3555.
- Smirnov B et al. Lupus erythematosus lichen planus overlap syndrome mimicking squamous cell carcinoma. *J Clin Aesthet Dermatol.* 2019; 12(9):36-8.
- Lospinoso DJ et al. Lupus erythematosus/lichen planus overlap syndrome: successful treatment with acitretin. *Lupus.* 2013;22(8):851-4.
- Lospinoso DJ et al. Lupus erythematosus/lichen planus overlap syndrome: successful treatment with acitretin. *Lupus.* 2013;22(8):851-4.
- Liu Y et al. The first reported case of bullous lichen planus-systemic lupus erythematosus overlap syndrome. *Front Med (Lausanne).* 2021;8:744592.
- Farley-Loftus R et al. Hypertrophic discoid lupus erythematosus. *Dermatol Online J.* 2010;16(11):1.
- Demirci GT et al. Lupus erythematosus and lichen planus overlap syndrome: a case report with rapid response to topical corticosteroid therapy. *Dermatol Reports.* 2011;3(3):e48.
- Sekar CS et al. SCLE-LP overlap syndrome. *Indian J Dermatol.* 2011;56(2):209-10.
- Scotti B et al. Hypertrophic lichen planus and hypertrophic skin lesions associated with histological lichenoid infiltrate: a case report and literature review. *Dermatopathology (Basel).* 2025;12(1):8.
- Idriss MH et al. Concomitant hypertrophic lichen planus and squamous cell carcinoma: clinical features and treatment outcomes. *Int J Dermatol.* 2022;61(12):1527-31.
- Mufti A et al. Squamous cell carcinoma arising within discoid lupus erythematosus lesions: a systematic review. *JAAD Int.* 2021;2:1-4.
- Sil A et al. Blaschkoid lichen planus occurring in childhood systemic lupus erythematosus. *Pediatr Dermatol.* 2020;37(3):579-81.
- Shapera EA, Kim PD. Squamous cell cancer arising in an African American male cheek from discoid lupus: a rare case and review of the literature. *Case Rep Surg.* 2016;2016:9170424.
- Shojaei D et al. Characteristics, management, and outcomes of cutaneous malignancies arising within discoid lupus erythematosus: a systematic review. *J Cutan Med Surg.* 2026;DOI:10.1177/12034754261427482.
- Lazarowitz R et al. Cutaneous squamous cell carcinoma arising in discoid lupus erythematosus: a systematic review and meta-analysis. *J Cutan Med Surg.* 2026;DOI:10.1177/12034754261437739.